4D Molecular Therapeutics (FDMT) PEG Ratio
Market Cap: $150.48M
Avg Volume: 829.83K
Industry: Biotechnology
Sector: Healthcare
PEG Ratio Summary
- 4D Molecular Therapeutics's trailing twelve month (TTM) PEG ratio is 0.45.
- 4D Molecular Therapeutics's annual PEG ratio as of today is -0.12.
- 4D Molecular Therapeutics's quarterly PEG ratio is -0.11.
What is the PEG Ratio?
The PEG ratio (Price/Earnings to Growth ratio) is a valuation metric for determining the relative trade-off between the price of a stock, the earnings generated per share (EPS), and the company's expected growth. A lower PEG ratio suggests that a stock may be undervalued given its earnings performance and growth potential.
How is the PEG Ratio calculated?
The PEG ratio is calculated by dividing the P/E ratio by the annual EPS growth. The formula is:
PEG Ratio = (P/E Ratio) / (EPS Growth Rate)
This helps investors to determine a stock's value while considering the company's earnings growth.
Related Metrics
Other important metrics to assess 4D Molecular Therapeutics's financial health include:
- P/E Ratio (Price to Earnings Ratio) - measures the company's current share price relative to its per-share earnings:
- Annual: -1.87
- Quarterly: -1.51
- TTM: -1.09
- P/S Ratio (Price to Sales Ratio) - compares the company's stock price to its revenues:
- Annual: 8120.72
- Quarterly: 300466.64
- TTM: 4067.10
- P/B Ratio (Price to Book Ratio) - compares the company's market value to its book value:
- Annual: 0.59
- Quarterly: 0.59
- TTM: 0.34
- P/CF Ratio (Price to Cash Flow Ratio) - compares the company's market value to its cash flow:
- Annual: -2.23
- Quarterly: -6.55
- TTM: -1.30
These metrics provide insights into 4D Molecular Therapeutics's financial health and its ability to meet short-term obligations. Comparing these ratios with industry benchmarks can offer a deeper understanding of the company's performance.
TTM PEG Ratio
0.45
Annual PEG Ratio
-0.12
Quarterly PEG Ratio
-0.11
4D Molecular Therapeutics Historical PEG Ratio
Historical P/E Ratio
Historical P/S Ratio
Historical P/B Ratio
Historical P/CF Ratio
4D Molecular Therapeutics Historical Financial Metrics
The table below shows various financial metrics for each year, with the latest data available for the last fiscal year 2024.
| Year | PEG Ratio | P/E Ratio | P/S Ratio | P/B Ratio | P/CF Ratio |
|---|---|---|---|---|---|
| 2024 | -0.12 | -1.87 | 8120.72 | 0.59 | -2.23 |
| 2023 | 0.45 | -7.86 | 38.26 | 2.58 | -10.46 |
| 2022 | -0.26 | -7.11 | 229.63 | -2.28 | -8.29 |
| 2021 | -0.56 | -8.91 | 33.73 | -2.94 | -8.80 |
| 2020 | -3.26 | -19.56 | 81.25 | 4.31 | -21.72 |
| 2019 | -0.12 | -20.27 | 153.59 | -14.70 | -29.23 |
| 2018 | 0.00 | -53.08 | 35.88 | -18.38 | -31.20 |
| 2017 | 0.00 | -53.54 | 103.77 | -30.67 | 72.94 |
Related Metrics
Explore detailed financial metrics and analysis for FDMT.